HighVista Strategies Invests $1.39M in ADMA Biologics

Biotechnology firm ADMA Biologics sees new investment from HighVista Strategies

Mar. 16, 2026 at 11:21am

Got story updates? Submit your updates here. ›

HighVista Strategies LLC, an investment management firm, has purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA), a biotechnology company based in Ramsey, New Jersey. HighVista Strategies acquired 95,112 shares of ADMA Biologics, valued at approximately $1.39 million, during the third quarter according to a recent SEC filing.

Why it matters

This investment from HighVista Strategies represents a vote of confidence in ADMA Biologics and its operations. As a biotechnology firm focused on plasma-derived biologics, ADMA Biologics has seen growing institutional investor interest as it works to address unmet needs in immune-compromised patient populations.

The details

HighVista Strategies, an investment management firm, purchased 95,112 shares of ADMA Biologics stock during the third quarter. This new stake is valued at approximately $1.39 million. ADMA Biologics is a biopharmaceutical company that focuses on the development, manufacturing, and commercialization of specialty plasma-derived biologics.

  • HighVista Strategies made the investment in ADMA Biologics during the third quarter of the year.

The players

HighVista Strategies LLC

An investment management firm that has purchased a new stake in ADMA Biologics Inc.

ADMA Biologics Inc

A biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived biologics.

Got photos? Submit your photos here. ›

The takeaway

This investment from HighVista Strategies demonstrates the growing institutional interest in ADMA Biologics as the company works to address unmet needs in the plasma-derived biologics market. The investment provides additional capital to support ADMA Biologics' ongoing operations and development efforts.